Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
The Vanguard Group amended its Schedule 13G for DaVita Inc. to report 0 shares of Common Stock following an internal realignment effective January 12, 2026. The filing states certain subsidiaries will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim on March 26, 2026.
Arway Pamela M reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Pamela M. Arway received an equity award of 332 shares of common stock, recorded at a grant price of $0.00 per share, as non-cash compensation. Following this grant, she directly owns 26,695 shares of DaVita common stock.
DaVita Inc. director Barbara J. Desoer received a stock award of 332 shares of common stock. The shares were acquired on March 15, 2026 as a grant with a stated price of $0.00 per share, indicating compensation rather than an open-market purchase.
Following this grant, Desoer directly holds 332 DaVita shares. She also has indirect ownership of 13,439 shares held through the “Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998,” giving her a combined reported position of 13,771 shares.
DaVita Inc. Chief Operating Officer David Paul Maughan reported equity compensation awards and related tax-withholding transactions. He received 14,351 stock appreciation rights tied to DaVita common stock at an exercise price of $150.7200 per share, expiring on March 15, 2031. He was also granted 5,308 shares of common stock as restricted stock units that are scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms.
On the same date, DaVita withheld 5,339 shares and 7,768 shares of common stock to cover tax obligations on the vesting of earlier restricted stock unit grants from March 15, 2022 and March 15, 2023. These F-code dispositions are payments of tax liability, not open-market sales. After these transactions, Maughan directly owns 114,467 shares of DaVita common stock.
YALE PHYLLIS R reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Phyllis R. Yale received a grant of 332 shares of Common Stock, bringing her direct holdings to 14,313 shares. This Form 4 reflects a compensation-related share award, not an open-market purchase or sale, and represents a routine insider equity grant.
DaVita Inc. CEO Javier Rodriguez received new equity awards as part of his compensation. He was granted 20,900 shares of common stock and 56,506 stock appreciation rights, each tied to an equivalent number of underlying common shares at an exercise price of $150.72 per share.
The common stock award increases his direct holdings to 909,815 shares. Both the restricted stock units and the stock appreciation rights are scheduled to vest in two equal installments, 50% on March 15, 2029 and 50% on March 15, 2030, subject to the terms and conditions of the applicable award agreements.
Pullin Dennis W reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Dennis W. Pullin received a grant of 332 shares of common stock. The award was recorded at a price of $0.00 per share, indicating it was compensation rather than a market purchase. Following this grant, he directly holds 2,421 DaVita common shares.
Hollar Jason M. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Jason M. Hollar received a grant of 332 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation-related grant or award. Following this transaction, he directly owns a total of 6,355 DaVita common shares.
BERRY CHRISTOPHER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. Chief Accounting Officer Christopher Michael Berry reported receiving a grant of 3,649 shares of Common Stock as a compensation-related award, recorded at $0.00 per share rather than an open-market purchase.
According to the footnote, these are restricted stock units scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to the applicable award terms. After this award, Berry directly holds 19,640 shares of DaVita common stock.
DaVita Inc. CFO and Treasurer Joel Ackerman reported routine equity compensation and related tax-withholding transactions. He received a grant of 15,427 Stock Appreciation Rights tied to common stock at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms. He also acquired 5,706 shares of common stock as a stock award, with related restricted stock units vesting 50% on the same future dates. To cover tax obligations from the vesting of prior performance stock units and restricted stock units, 42,820 shares of common stock were withheld rather than sold in the open market, through three F-code transactions at a reference price of $150.72 per share. After these awards and tax withholdings, Ackerman directly holds 183,905 shares of DaVita common stock, reflecting ongoing equity-based compensation and associated tax settlements rather than discretionary open-market trades.